SESEN BIO INC: Diferență între versiuni
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 1: | Linia 1: | ||
Pagina dedicata companiei SESEN BIO INC listata cu simbolul US.SESN | Pagina dedicata companiei SESEN [[BIO]] INC listata cu simbolul US.SESN | ||
==Descriere companie== | ==Descriere companie== | ||
Versiunea curentă din 28 noiembrie 2024 08:16
Pagina dedicata companiei SESEN BIO INC listata cu simbolul US.SESN
Descriere companie[edit | ]
Sesen Bio, Inc. (https://sesenbio.com/) is a late-stage clinical company providing targeted fusion protein therapeutics (TFPTs) for the treatment of patients with cancer. Its product pipeline includes Vicinium, which is composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The Company's product candidates are based on its TFPT platform and are focused on addressing areas of unmet medical need in cancer. TFPTs are single protein therapeutics composed of targeting domains genetically fused via peptide linkers to cytotoxic protein payloads that are produced through its recombinant one-step, microbial manufacturing process.
Grafic actiuni companie[edit | ]